Literature DB >> 21082503

Identification of the high-risk patient for ovarian hyperstimulation syndrome.

Evangelos G Papanikolaou1, Peter Humaidan, Nikolaos P Polyzos, Basil Tarlatzis.   

Abstract

Ovarian hyperstimulation syndrome (OHSS), an iatrogenic complication of ovarian stimulation for assisted reproduction, is a potentially life-threatening condition. Exogenous human chorionic gonadotropin (hCG) administered for final oocyte maturation and endogenous hCG produced by a developing pregnancy are fundamental in the development of the disease. Vascular endothelial growth factor is the key molecule mediating the pathophysiology of the syndrome, and genetic predisposition might play a role. Because the most severe cases are usually the late OHSS cases that occur when a pregnancy is established, several predictive markers have been introduced to identify the high-risk patient profile and consequently develop preventive strategies. This article reviews the most recent evidence evaluating the accuracy of different OHSS prediction parameters. Stratification was attempted according to the phase of the ovarian stimulation that the patients undergo. Anti-Müllerian hormone and the number of follicles seen on ultrasound seem promising discriminating factors, whereas prediction models that include age, antral follicle count, and estrogen levels on the day of ovulation triggering provide variable sensitivity and specificity. Until reliable genetic tests are available, and considering that the occurrence of pregnancy is unpredictable, the use of prognostic factors will be mainly indicative of risk rather than preventive of OHSS. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21082503     DOI: 10.1055/s-0030-1265671

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  10 in total

1.  GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.

Authors:  Yannis Prapas; Konstantinos Ravanos; Stamatios Petousis; Yannis Panagiotidis; Achilleas Papatheodorou; Chrysoula Margioula-Siarkou; Assunta Iuliano; Giuseppe Gullo; Nikos Prapas
Journal:  J Assist Reprod Genet       Date:  2017-08-03       Impact factor: 3.412

2.  Micro-dose hCG as luteal phase support without exogenous progesterone administration: mathematical modelling of the hCG concentration in circulation and initial clinical experience.

Authors:  C Yding Andersen; R Fischer; V Giorgione; Thomas W Kelsey
Journal:  J Assist Reprod Genet       Date:  2016-07-22       Impact factor: 3.412

Review 3.  Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.

Authors:  Klaus Fiedler; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2012-04-24       Impact factor: 5.211

4.  Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study.

Authors:  George T Lainas; Efstratios M Kolibianakis; Ioannis A Sfontouris; Ioannis Z Zorzovilis; George K Petsas; Theoni B Tarlatzi; Basil C Tarlatzis; Trifon G Lainas
Journal:  Reprod Biol Endocrinol       Date:  2012-08-31       Impact factor: 5.211

5.  New algorithm for OHSS prevention.

Authors:  Evangelos G Papanikolaou; Peter Humaidan; Nikos Polyzos; Sofia Kalantaridou; Sahar Kol; Claudio Benadiva; Herman Tournaye; Basil Tarlatzis
Journal:  Reprod Biol Endocrinol       Date:  2011-11-03       Impact factor: 5.211

Review 6.  Prevention of Ovarian Hyperstimulation Syndrome: A Review.

Authors:  Vinayak Smith; Tiki Osianlis; Beverley Vollenhoven
Journal:  Obstet Gynecol Int       Date:  2015-05-14

Review 7.  Agonist triggering in oocyte donation programs-Mini review.

Authors:  Robert Najdecki; Georgios Michos; Nikos Peitsidis; Evangelia Timotheou; Tatiana Chartomatsidou; Stelios Kakanis; Foteini Chouliara; Apostolos Mamopoulos; Evangelos Papanikolaou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-26       Impact factor: 6.055

8.  The dual trigger study: Rationale and study design of a prospective double-blind randomized clinical trial comparing pregnancy rates after co-administration of low dose hCG at the time of GnRH agonist trigger or 35 h later for the prevention of OHSS.

Authors:  Daniel Griffin; Claudio Benadiva; Tara Budinetz; Carolina Sueldo; Andrea DiLuigi; John Nulsen; Lawrence Engmann
Journal:  Contemp Clin Trials Commun       Date:  2017-08-17

9.  COMFFETI, Combined Fresh and Frozen Embryo Transfers per Individual: A New Index of Quality Control for The Performance of emberyologic Labs in The Emerging Era of Segmentation of Cycle and Freeze-All Strategy.

Authors:  Evangelos G Papanikolaou; Evi Timotheou; Petroula Tatsi; Hieronymus Janssens; Michael Grynberg; Apostolos Athanasiadis; Christina Zafeirati; Robert Najdecki; Stamatios Petousis
Journal:  Int J Fertil Steril       Date:  2018-10-02

Review 10.  Individualized luteal phase support after fresh embryo transfer: unanswered questions, a review.

Authors:  Jing Zhao; Jie Hao; Yanping Li
Journal:  Reprod Health       Date:  2022-01-22       Impact factor: 3.223

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.